Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Future prospects for CAR-T cell therapy in AML

Saad Kenderian • 5 Oct 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia CAR-T

Saad Kenderian, MB, ChB, Mayo Clinic, Rochester, MN, shares some insights into future prospects for CAR-T cell therapy in acute myeloid leukemia (AML), highlighting the challenges of using CAR-T products in AML, and future outlooks. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saad Kenderian

4:22
Current challenges in CAR-T cell therapy and the role of the tumor microenvironment
Saad Kenderian • 5 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals